Sanofi Pasteur

C. diff vaccine moves closer to reality with launch of large Phase III trial

C. diff vaccine moves closer to reality with launch of large Phase III trial

By

A potential Clostridium difficile vaccine performed well in initial tests and now has moved into a large Phase III trial, researchers announced today. The news from developer Sanofi Pasteur raises hopes that the antibiotic-resistant infection can be prevented in long-term care facilities and other settings where it has become a deadly scourge.